Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTRAIL I: CFZ533 versus tacrolimus-based standard of care in de novo liver transplant recipients
NL-OMON55608Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iscalimab in liver transplant (3 arms), sponsored by Novartis. Primary endpoint: Composite efficacy failure at Month 12. Started Feb 2020; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
liver transplant
Beyond the preview
Go deeper on NL-OMON55608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55608.